Companies / Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

Nasdaq: TCRTCIK 1107421FORT LAUDERDALE, FLziopharm.com

Financials · FY2025

Revenue$5.0K
Net income$-4.18M
Total debt$0
Cash$354.0K
Diluted EPS$-2.20
Shares outstanding24.4M

Ownership

24.4M shares outstanding · as of May 15, 2026
0.42%Insiders
Ownership
Insiders0.42%101,671
Institutions0.43%103,860
Public float99.16%24,216,615

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
0.21%50,146
Vieser JaimeDirector
0.16%38,853
Jerman Michael AllenFormerDirector
0.06%15,621
Weis HolgerCEOChief Executive Officer
0.05%12,672

Institutional holders 29

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Two Sigma Investments, LP
13F manager
TrimCommon Stock$-22.2K-8K
-41.69%
10,839
0.04% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$8.1K+3K
+14.31%
22,560
0.09% of shares
low
Q1 2026
as of
Royal Bank of Canada
13F manager
NewCommon Stock$1.0K+185
185
<0.01% of shares
low
Q2 2025
as of
Barclays PLC
13F manager
TrimCommon Stock$-344-71
-41.52%
100
<0.01% of shares
low
Q1 2025
as of
Barclays PLC
13F manager
NewCommon Stock$251+171
171
<0.01% of shares
low
Q4 2025
as of
Barclays PLC
13F manager
ExitCommon Stock$-121-50
-100.00%
0
low
Q3 2025
as of
Barclays PLC
13F manager
TrimCommon Stock$-121-50
-50.00%
50
<0.01% of shares
low
Q4 2025
as of
Tucker Asset Management LLC
13F manager
NewCommon Stock$3+1
1
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TCRTCommon StockEquity98973P309BBG000FWCC57